Emerging leader in rapid immunoassay tests for infectious diseases selects Global 2.0 to manage its medical devices approvals and submissions worldwide.
Framingham, MA, January 12, 2006 – clinivation, Inc. announced today that StatSure Diagnostic Systems, Inc. (NASDAQ NM: SVAD) has selected clinivation Global™ 2.0 software.
“StatSure Diagnostics is an emerging leader in next-generation diagnostic testing applications for important infectious diseases and other medical conditions, and we are pleased they have selected clinivation Global 2.0 to help them build and track their medical device approvals and submissions worldwide,” said Joseph Kozikowski, M.D., clinivation’s Chief Executive Officer.
Clinivation Global 2.0 software enables medical device companies to sell more products to more countries faster and easier than ever before. Global 2.0 is the first complete solution targeted at automating the business processes for medical device approvals worldwide.
About StatSure Diagnostic Systems, Inc.
StatSure Diagnostic Systems is engaged in the development, manufacture and marketing of rapid immunoassay tests for the detection of sexually transmitted and other infectious diseases; in addition, the Company has developed and is marketing a product line of patented, oral-fluid collection devices. The Company’s proprietary platforms provide significant customer benefits and competitive advantages as compared to similar products that are currently available. Improved accuracy, operator convenience, and reduced risk of infection from collecting and handling specimens, have been engineered into SDS products. All of our diagnostic tests are based on the same easy-to-use technology platform, thus facilitating the development of future products. StatSure Diagnostic System’s technology provides a quick, accurate, portable, safe and cost-effective solution.
Visit StatSure Diagnostics online at www.statsurediagnostics.com